Clinical Trials Browser

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04161248 2026-02-02

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase EARLY_PHASE1 Recruiting

18 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

Phase 1 Active not recruiting

23 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Phase 1 Recruiting

54 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02741388 2021-12-07

SELINDA

Phase 1 Completed

39 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, B-Cell

NCT00413959 2018-09-19

VRCD

Phase 2 Terminated

12 enrolled 7 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02983097 2018-01-19

R²-DHAP

Phase 1/2 Terminated

34 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Clinical Trials

OLYMPIA-4

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Venetoclax Plus Inotuzumab for B-ALL

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

SELINDA

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

VRCD

R²-DHAP